We recently published a list of Billionaire George Soros’ 10 Small-Cap Stocks with Huge Upside Potential. In this article, we ...

Piper Sandler analyst Biren Amin maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report) today and set a price target of ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on scPharmaceuticals (SCPH – Research Report) and ...

Sarepta Therapeutics Inc. research and ratings by Barron's. View SRPT revenue estimates and earnings estimates, as well as in-depth analyst breakdowns.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was ...

This afternoon we watched Sarepta Therapeutics rise 5.6% to a price of $58.34 per share. The Mid-Cap Pharmaceutical company is now trading -60.85% below its average target price of $149.0. Analysts ...

It's been nearly two years since Elevidys, a gene therapy for Duchenne MD developed by Sarepta Therapeutics, was approved by ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first ...

We recently published a list of the 11 Most Promising Long-Term Stocks According to Analysts. In this article, we are going ...

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or "the Company") for ...

Shares of gene therapy companies — including Sarepta Therapeutics — got a lift Monday after FDA's Marty Makary laid out his plans.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, ...